Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 23 clinical trials
Featured trial
Formal Test 5

Formal Test 5Formal Test 5Formal Test 5

  • 0 views
  • 19 Feb, 2024
  • 1 location
Featured trial
Formal Test 6

Formal Test 6Formal Test 6Formal Test 6Formal Test 6Formal Test 6Formal Test 6Formal Test 6

  • 0 views
  • 19 Feb, 2024
  • 1 location
Featured trial
Formal Test 7  

Formal Test 7Formal Test 7Formal Test 7Formal Test 7Formal Test 7Formal Test 7Formal Test 7Formal Test 7Formal Test 7Formal Test 7Formal Test 7Formal Test 7

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study Evaluating The Safety Tolerability Pharmacokinetics And Efficacy Of Venetoclax In Combination With Atezolizumab Carboplatin And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

A study consisting of a dose-escalation phase and a dose-expansion phase to evaluate the safety, tolerability, pharmacokinetics, and efficacy of venetoclax in combination with atezolizumab, carboplatin, and etoposide.

maintenance therapy
colony stimulating factor
g-csf
cancer chemotherapy
atezolizumab
  • 0 views
  • 19 Feb, 2024
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be randomized in a 1:1 ratio to receive one of the following treatment regimens during …

solid tumour
carboplatin
measurable disease
etoposide
atezolizumab
  • 0 views
  • 19 Feb, 2024
Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion

The aim of the study is to evaluate the safety and feasibility of a hypofractionated, accelerated radiation approach based on the incidence of grade 3-5 NCI Common Terminology Criteria for Adverse Events (NCI-CTC-AE ) toxicity and / or termination of the planned therapy for any reason with neoadjuvant radiation with …

  • 0 views
  • 19 Feb, 2024
MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma

The proposed study is a two-step trial with 1) a safety run in part conducted in pediatric patients and 2) a Phase II part in adult and pediatric patients aiming to evaluate the safety and clinical activity of atezolizumab + cobimetinib in advanced/metastatic soft tissue sarcomas.

rhabdoid tumors
cobimetinib
atezolizumab
adjuvant
cancer
  • 0 views
  • 19 Feb, 2024
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

Small cell lung cancer (SCLC) is a rapidly proliferating, neuroendocrine tumor that accounts for about 15% of all lung cancers. Most patients have metastases at primary diagnosis involving sites like bone, adrenal glands, liver and brain. Compared with non-small-cell lung cancer (NSCLC) SCLC has a unique natural history with a …

tuberculosis
cancer
ipilimumab
small cell lung cancer
systemic disease
  • 0 views
  • 19 Feb, 2024
Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276

Patients with refractory and/or recurrent solid tumor have poor prognosis despite complex multimodel therapy and therefore, novel approaches are urgently needed. This study attempts to treat these diseases using T cells genetically modified with a 4th generation lentiviral chimeric antigen receptor (4SCAR fused with an inducible apoptotic caspase 9 domain) …

blood transfusion
immunohistochemistry
recurrent solid tumor
kidney function test
serum bilirubin
  • 0 views
  • 19 Feb, 2024
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

carboplatin paclitaxel
endometrial carcinoma
adjuvant
cancer
durvalumab
  • 0 views
  • 19 Feb, 2024